Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announced broad alignment with the FDA regarding the registration path for its CRB-701 treatment.

• Corbus Pharmaceuticals stock is showing weakness. What’s driving CRBP stock lower?

FDA Alignment On Corbus Lead Drug Path

Corbus Pharmaceuticals on Tuesday received FDA feedback that allows it to proceed with the proposed registrational study design for CRB-701, targeting second-line head and neck squamous cell carcinoma (HNSCC) and cervical cancer.

The agreed-upon second-line registrational study designs for CRB-701 include:

• HNSCC: a single, randomized controlled study of CRB-701 compared to physicians’ choice chemotherapy with potential accelerated approval using objective response rate (ORR) as the primary endpoint and potential full approval granted on overall survival (OS) benefit.
• Cervical cancer: a single, randomized controlled study exploring the efficacy and safety of CRB-701 compared to physicians’ choice of chemotherapy or Pfizer Inc. (NYSE:PFE)/Genmab A/S – ADR (NASDAQ:GMAB) Tivdak (tisotumab vedotin-tftv) with potential accelerated approval using ORR as the primary endpoint and potential full approval granted on OS benefit.

Analyst Sees Differentiation

William Blair wrote that Corbus's lead program, CRB-701, is commercially de-risked through Pfizer’s Padcev, which shares the same nectin-4 target.

However, CRB-701 can differentiate itself from Padcev and other nectin-4-targeted ADCs through an extended half-life and improved linker stability, leading to a more convenient dosing regimen and superior efficacy and safety.

Analyst Andy Hsieh sees considerable upside to the current enterprise value when juxtaposed with the total U.S. HNSCC market opportunity. In addition, Corbus's second program, CRB-913, which is being developed as a therapeutic intervention for weight management, could provide upside optionality.

Hsieh says recent promising Phase 1/2 data for CRB-701 and the exposure to the obesity field, which could reach over $100 billion by the early 2030s, according to William Blair’s analysis.

The analyst reiterates an Outperform rating on Corbus shares.

CRBP Stock Price Activity: Corbus Pharmaceuticals shares were down 3.45% at $9.79 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock